Article

Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer

Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
International journal of radiation oncology, biology, physics (Impact Factor: 4.18). 03/2012; 83(1):e21-7. DOI: 10.1016/j.ijrobp.2011.11.065
Source: PubMed

ABSTRACT In chemoradiation (CRT)-based bladder-sparing approaches for muscle invasive bladder cancer (MIBC), patients who respond favorably to induction CRT enjoy the benefits of bladder preservation, whereas nonresponders do not. Thus, accurate prediction of CRT sensitivity would optimize patient selection for bladder-sparing protocols. Diffusion-weighted MRI (DW-MRI) is a functional imaging technique that quantifies the diffusion of water molecules in a noninvasive manner. We investigated whether DW-MRI predicts CRT sensitivity of MIBC.
The study cohort consisted of 23 MIBC patients (cT2/T3 = 7/16) who underwent induction CRT consisting of radiotherapy to the small pelvis (40 Gy) with two cycles of cisplatin (20 mg/day for 5 days), followed by partial or radical cystectomy. All patients underwent DW-MRI before the initiation of treatment. Associations of apparent diffusion coefficient (ADC) values with CRT sensitivity were analyzed. The proliferative potential of MIBC was also assessed by analyzing the Ki-67 labeling index (LI) in pretherapeutic biopsy specimens.
Thirteen patients (57%) achieved pathologic complete response (pCR) to CRT. These CRT-sensitive MIBCs showed significantly lower ADC values (median, 0.63 × 10(-3) mm(2)/s; range, 0.43-0.77) than CRT-resistant (no pCR) MIBCs (median, 0.84 × 10(-3) mm(2)/s; range, 0.69-1.09; p = 0.0003). Multivariate analysis identified ADC value as the only significant and independent predictor of CRT sensitivity (p < 0.0001; odds ratio per 0.001 ×10(-3) mm(2)/s increase, 1.03; 95% confidence interval, 1.01-1.08). With a cutoff ADC value at 0.74 × 10(-3) mm(2)/s, sensitivity/specificity/accuracy in predicting CRT sensitivity was 92/90/91%. Ki-67 LI was significantly higher in CRT-sensitive MIBCs (p = 0.0005) and significantly and inversely correlated with ADC values (ρ = -0.67, p = 0.0007).
DW-MRI is a potential biomarker for predicting CRT sensitivity in MIBC. DW-MRI may be useful to optimize patient selection for CRT-based bladder-sparing approaches.

0 Followers
 · 
123 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To evaluate the role of diffusion-weighted MRI (DW-MRI) as an imaging biomarker for UUTC which has already metastasized or will metastasize soon. Methods: Sixty-one patients clinically diagnosed with UUTC were prospectively enrolled in this study. All the patients underwent MRI including DW-MRI prior to any interventions. Correlations between apparent diffusion coefficient (ADC) and other clinicopathological variables including metastasis-free survival were analysed. Results: Median follow-up period was 938 days. Of 61 patients, 12 patients had any metastases at the initial diagnosis. Eleven patients developed metastases during the follow-up period. These 23 patients were categorized as 'Metastatic'. Of the remaining 38 patients, 35 with a follow-up period longer than 400 days were categorized as 'Localized'. ADC was significantly lower in 'Metastatic' than in 'Localized' (p = 0.0002). Multivariate analysis of preoperative variables identified ADC (cut-off value: 1.08 × 10(-3) mm(2)/s) and clinical T stage based on T2-weighted MRI (T2W-MRI) as an independent predictive factor of metastatic UUTC. Forty-six patients without any metastases at the initial diagnosis were stratified into high-risk group (16 patients with low ADC and clinical T3-4) and low-risk group (30 patients with high ADC or clinical Ta-2). The 3-year metastasis-free survivals were 45% and 93%, respectively. Conclusions: In the current study, UUTC with lower ADC value is more likely to have metastatic potential. Incorporating ADC with clinical T stage helps to differentiate metastatic UUTC at the initial diagnosis. Advances in knowledge: DW-MRI is a potential imaging biomarker reflecting metastatic propensity of UUTC.
    British Journal of Radiology 07/2014; 87(1042):20130791. DOI:10.1259/bjr.20130791 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore associations of whole-lesion histogram diffusion metrics with pathologic findings and subsequent metastatic disease in bladder cancer patients undergoing radical cystectomy.
    Abdominal Imaging 08/2014; DOI:10.1007/s00261-014-0213-y · 1.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diffusion-weighted magnetic resonance imaging is a type of functional imaging that is increasingly being applied in the management of upper tract urothelial carcinoma and bladder cancer. The image contrast is derived from differences in the Brownian motion of water molecules in tissues. The homogenous high signal intensity of upper tract urothelial carcinoma and bladder cancer on diffusion-weighted magnetic resonance imaging provides helpful diagnostic information for the presence of cancerous lesions in a non-invasive manner. Recently, growing evidence has emerged showing that diffusion-weighted magnetic resonance imaging can serve as an imaging biomarker for characterizing cancer pathophysiology, because the signal reflects biophysical information about the tissues. Quantitative analysis by evaluating the apparent diffusion coefficient values potentially reflects the histological grade and the biological aggressiveness of urothelial carcinoma. The apparent diffusion coefficient value could be a biomarker predicting the clinical course of upper tract urothelial carcinoma and bladder cancer. In addition, in chemoradiotherapy-based bladder-sparing approaches against muscle-invasive bladder cancer, the role of diffusion-weighted magnetic resonance imaging for predicting the chemoradiosensitivity and for monitoring therapeutic response has been shown. Diffusion-weighted magnetic resonance imaging is expected to improve the diagnostic accuracy, and this qualitative information might allow individualized treatment strategies for patients with urothelial carcinoma.
    International Journal of Urology 08/2014; DOI:10.1111/iju.12587 · 1.80 Impact Factor